A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)

BACKGROUND: Angiogenesis is implicated in the pathophysiology and progression of myelodysplastic syndromes (MDS). Vatalanib (PTK787/ZK222584; Novartis and Schering AG) inhibits receptor tyrosine kinases of vascular endothelial growth factor, platelet derived growth factor and c-Kit. We examined whet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gupta, Pankaj, Mulkey, Flora, Hasserjian, Robert P., Sanford, Ben L., Vij, Ravi, Hurd, David D., Odenike, Olatoyosi M., Bloomfield, Clara D., Owzar, Kouros, Stone, Richard M., Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3773017/
https://ncbi.nlm.nih.gov/pubmed/23700288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9978-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados